Colistin-rifampin Combination and Colistin Monotherapy in Extensively Drug-resistant Acinetobacter Baumannii

• Status: Completed
• Trial end date: 2018-06-21
• Target enrollment: 0
• Participant gender: All

Summary

The investigators aimed to confirm the utility of the synergy test results (E-tesT) in vitro to predict the efficacy and safety of colistin-rifampin combination and colistin monotherapy in extensively drug-resistant acinetobacter baumannii.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Gangnam Severance Hospital
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular; Colistin; Rifampin

Criteria

Inclusion Criteria:

• Pneumonia, blood septicemia, urinary tract infection, or other infection or even colonization with evidence of extensively drug-resistant Acinetobacter baumannii infection

Exclusion Criteria:

• Hypersensitivity reaction to colistin or rifampin

• use of colistin or rifampin in 15 days prior to screening

• evidence of extensively drug-resistant Acinetobacter baumannii infection in 15 days prior to screening

• CLcr < 15 mL/min, ALT or AST > 3xULN, total bilirubin > 2xULN, Hb < 7 gm/dL, ANC < 500/mm3, Platelet < 50,000/mm3